OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner




  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended for other attorneys. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-2017

« Federal Circuit Sidesteps Interesting Questions of Jurisdiction Under 271(e)(2) and Inducement of Infringement in Ropivacaine Case | Main | District Court Dismisses AstraZeneca's Patent Suits Against Crestor (Rosuvastatin) ANDA Applicants Who Filed Section viii Statements, Finding No Valid Claims Under 35 USC 271(e)(2) »

November 14, 2010


senthil kumar

crospovidone effect as a stabilizer was patented by Teva, the conception and reduction of practice by Astrageneca rendered the novelty unpatentable eventhough Astrageneca did not appreciate the role of the crospovidone as a stabilizer

The comments to this entry are closed.